Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Tislelizumab with Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT06646588Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Fourth Hospital of Hebei Medical University. Started Apr 2024; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06646588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646588.